1. Home
  2. BMRN vs CHTR Comparison

BMRN vs CHTR Comparison

Compare BMRN & CHTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

HOLD

Current Price

$56.34

Market Cap

12.3B

Sector

Health Care

ML Signal

HOLD

Logo Charter Communications Inc. New

CHTR

Charter Communications Inc. New

SELL

Current Price

$109.90

Market Cap

12.5B

ML Signal

SELL

Company Overview

Basic Information
Metric
BMRN
CHTR
Founded
1996
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
12.5B
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
BMRN
CHTR
Price
$56.34
$109.90
Analyst Decision
Buy
Hold
Analyst Count
28
21
Target Price
$91.59
★ $173.17
AVG Volume (30 Days)
2.1M
★ 2.7M
Earning Date
10-30-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.55
EPS
0.77
★ 19.81
Revenue
$1,313,646,000.00
★ $54,774,000,000.00
Revenue This Year
$21.42
$7.52
Revenue Next Year
$14.51
$11.50
P/E Ratio
$70.97
★ $5.54
Revenue Growth
★ 17.62
N/A
52 Week Low
$49.26
$101.63
52 Week High
$70.98
$254.11

Technical Indicators

Market Signals
Indicator
BMRN
CHTR
Relative Strength Index (RSI) 31.35 40.51
Support Level $53.61 $101.63
Resistance Level $57.95 $149.20
Average True Range (ATR) 1.42 4.13
MACD -0.06 1.41
Stochastic Oscillator 11.06 72.51

Price Performance

Historical Comparison
BMRN
CHTR

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

About CHTR Charter Communications Inc. New

Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 59 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (Los Angeles Lakers), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1. Charter plans to acquire cable peer Cox.

Share on Social Networks: